Comprehensive analysis of epigenetic and epitranscriptomic genes' expression in human NAFLD

Area of Science:

• Hepatology
• Molecular Biology
• Epigenetics

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a growing global health concern, driven by the obesity epidemic.
• Its complex development and progression mechanisms remain poorly understood.
• Epigenetic and epitranscriptomic alterations are implicated in chronic liver diseases.

Purpose of the Study:

• To comprehensively analyze epigenetic and epitranscriptomic gene expression in NAFLD.
• To identify gene expression signatures associated with NAFLD progression and liver fibrosis.
• To explore potential drug targets for NAFLD treatment.

Main Methods:

• Integrated analysis of ten transcriptomic datasets from 903 liver tissue samples.
• Included samples from normal livers, obese patients, non-alcoholic fatty liver (NAFL), and non-alcoholic steatohepatitis (NASH).
• Examined expression of epigenetic/epitranscriptomic genes and related metabolic enzymes.

Main Results:

• Detailed landscape of epigenetic and epitranscriptomic gene expression across NAFLD stages.
• Identified significant gene expression dysregulation linked to disease progression, particularly fibrosis.
• Discovered novel epigenetic/epitranscriptomic effectors with potential pathogenic roles in human NAFLD.

Conclusions:

• Altered epigenetic and epitranscriptomic gene expression is a key feature of NAFLD pathogenesis.
• Identified gene signatures may indicate disease progression and fibrosis development.
• Findings offer new insights into NAFLD and potential therapeutic strategies, including targeting hepatocellular carcinoma progression.